Join to View Full Profile
12902 Usf Magnolia DrTampa, FL 33612
Phone+1 813-745-5768
Dr. Agresta is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- University of South Florida Morsani College of Medicine/Moffitt Cancer Center/Tampa General HospitalFellowship, Hematology and Medical Oncology, 2003 - 2006
- Tulane UniversityResidency, Internal Medicine, 1999 - 2003
- Tulane University School of MedicineClass of 1999
Certifications & Licensure
- FL State Medical License 2006 - 2012
Clinical Trials
- A Phase I Study of AG-348 in Healthy Volunteers Start of enrollment: 2014 Mar 01
- A Phase I Study of AG-348 in Healthy Volunteers Start of enrollment: 2014 May 01
- Food Effect Study of AG-221 in Healthy Male Subjects Start of enrollment: 2014 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- A Phase 1 Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients With Advanced Myeloid Malignancies.Courtney D DiNardo, Amir T Fathi, Ashwin Kishtagari, Kapil N Bhalla, Alfonso Quintás-Cardama
Clinical Cancer Research. 2025-04-16 - A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors.J Andrew Livingston, Jean-Yves Blay, Jonathan Trent, Claudia Valverde, Mark Agulnik
Clinical Cancer Research. 2025-02-17 - 20 citationsClinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutationBin Fan, David Dai, Courtney D. DiNardo, Eytan M. Stein, Stéphane de Botton
Cancer Chemotherapy and Pharmacology. 2020-04-15
Press Mentions
- Therapeutics Expands Leadership Team with Two C-suite AppointmentsSeptember 16th, 2019
- Infinity Pharmaceuticals Announces Transition of Samuel Agresta, M.D., from Chief Medical Officer to Board of DirectorsAugust 22nd, 2019
- Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Ratings Summary as of Dec 18, 2018December 18th, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: